High Response Rates to CAR-T Seen in Mantle Cell Lymphoma
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic. -
BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma. -
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia. -
CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
VIDEO SERIES
LYMPHOMA NEWS
DLBCL-Type Richter Transformation Associated With Worse Prognosis vs DLBCL
Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine
Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma
Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma
Psoriasis Linked to Increased Risk for Developing Cancer
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
